US EditionClearmind initiates first U.S. trial of CMND-100 in AUD at Johns Hopkins - BioTuesdays
Summary by biotuesdays.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Clearmind initiates first U.S. trial of CMND-100 in AUD at Johns Hopkins - BioTuesdays
Clearmind Medicine (NASDAQ:CMND; FSE:CWYO) announced the initiation of its first U.S.-based Phase 1/2a trial of CMND-100 in alcohol use disorder (AUD) at the Johns Hopkins University School of Medicine. According to Clearmind, the first in human clinical trial will investigate the safety, tolerability and full pharmacokinetic profile of Clearmind’s proprietary MEAI-based oral drug candidate, CMND-100, developed as a breakthrough treatment for AU…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
